Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus THEOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus THEOBID.
DILOR-400 vs THEOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/mL). Max 600 mg/day unless serum levels monitored.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Neonates: 24-36 h; Children (1-9 y): 3-4 h; Adults (non-smokers): 6-12 h; Adults (smokers): 4-5 h; Hepatic cirrhosis: prolonged (up to 30 h); Heart failure: prolonged (up to 20 h).
Renal (70% unchanged), hepatic metabolism (30%)
Renal (10% unchanged), hepatic metabolism (90%, primarily via CYP1A2 and CYP3A4); 20% excreted in feces as metabolites.
Category C
Category C
Bronchodilator
Bronchodilator